Researchers identify drug against the formation of metastasis

Basel researchers identify drug against the formation of metastasis
The image represents an artistic coloration of a cluster of circulating tumor cells (CTCs), isolated from the blood of a patient with breast cancer, trapped on a microfluidic device. Credit: M Oeggerli / Micronaut 2018, supported by Pathology-, C-CINA / Biozentrum-, and I Krol, and N Aceto, Faculty of Medicine-, University Hospital and University Basel.

The most deadly aspect of breast cancer is metastasis, cancer cells spreading throughout the body. Researchers at the University and the University Hospital of Basel have now discovered a substance that suppresses the formation of metastases. In the journal Cell, the team of molecular biologists, computational biologists and clinicians reports on their interdisciplinary approach.

The development of is responsible for more than 90 percent of -related deaths, and patients with a metastatic disease are considered incurable. The interdisciplinary team led by Prof. Nicola Aceto from the Department of Biomedicine at the University of Basel has identified a drug that suppresses the spread of malignant cancer and their metastasis-seeding ability.

Precursors of metastases: Circulating tumor cell clusters

Circulating (CTCs) are cancer cells that leave a primary tumor and enter the bloodstream, on their way to seeding distant metastases. These so-called CTCs can be found in the blood of patients as single cells or cell clusters. CTC clusters are the precursors of metastases. The Basel research team has discovered that CTC cluster formation leads to key that facilitate metastasis seeding. These changes enable CTC clusters to mimic some properties of embryonic stem cells, including their ability to proliferate while retaining tissue-forming capabilities. The scientists have also shown that these epigenetic changes are fully reversible upon the dissociation of CTC clusters.

In their search for a substance that suppresses metastasis development, the research team tested 2486 FDA-approved compounds used for a number of different indications. They found inhibitors with the unexpected ability to dissociate patient-derived CTC clusters. This drug-based dissociation of CTC clusters into individual cells also resulted into epigenetic remodeling and prevented the formation of new metastases.

Preventing metastasis versus killing cancer cells

"We thought of acting differently from standard approaches, and sought to identify drugs that do not kill , but simply dissociate them," states Nicola Aceto, holder of an ERC starting grant and SNSF professorship.

In the fight against breast cancer, metastases remain the greatest danger. These new findings on the mechanisms of metastasis formation are the result of a large collaborative effort across various disciplines. "Our ambitious approach would not have been possible without collaboration with outstanding clinicians, molecular and computational biologists, with the support of state-of-the-art technology platforms," says Aceto and adds: "Our methodology is positioned directly at the interface between these different disciplines. We are already working on the next step, which is to conduct a clinical trial with breast cancer patients."


Explore further

Circulating tumor cell clusters more likely to cause metastasis than single cells

More information: Cell (2019). DOI: 10.1016/j.cell.2018.11.046
Journal information: Cell

Citation: Researchers identify drug against the formation of metastasis (2019, January 10) retrieved 20 May 2019 from https://medicalxpress.com/news/2019-01-drug-formation-metastasis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1550 shares

Feedback to editors

User comments

Jan 15, 2019
These are the kinds of research that needs to be done for all types of cancer which can save and prolong lives. Sometimes I wonder if cancer researchers need a consortium which can guide them to focus on the most important topics and monitor the lifetime of the research.
Also the implementations of the new researches are taking way too long to make an effect on the lives of cancer patients as they are dying with the primitive treatments that are available in the clinics and hospitals todate. It is sad that we have commercialised this field and everybody is after making big money. God help the patients.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more